WHO Issues Alert Over Severe Scarcity of Weight-Loss Jabs

Under a tenth of individuals eligible to benefit from weight-loss injections such as Wegovy are able to get them, warns the WHO as it releases its initial recommendations on the therapies.

With over a billion individuals worldwide now obese, it is urging increased and just availability to GLP-1 medication.

Based on estimates, more than two billion are projected to be living with obesity by 2030 unless action is taken.

"The new guidance acknowledges that obesity is a lifelong illness that can be addressed with thorough and continuous care," remarked the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and logistical bottlenecks are significant barriers to universal access to the treatments that can assist patients in reducing significant body mass, explains the agency.

Skinny Jab Scarcity

Even in the present most favorable scenario, the production of such drugs could only cover around 100 million people – fewer than 10% of the global need, as stated by the WHO.

The advice calls on nations and manufacturers to widen availability, through approaches like patent sharing.

The intellectual property rights on a key compound – the main component of the drug Wegovy – is scheduled to end in several nations in 2026.

How Obesity Jabs Function

The injections imitate a body's own hormone to slow digestion, suppress the appetite and increase the sense of being full so people eat less.

Patients typically see weight reduction in the initial weeks of beginning the weekly injections.

Studies suggests people may see weight return after a year of stopping the medication, because their typical hunger return.

To be carrying excess weight raises your likelihood for developing medical conditions, including diabetes, heart disease, stroke, and certain cancers.

Excess weight concerns people in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, per the health agency.